Literature DB >> 2344440

Serine proteinase requirement for the extra-cellular metabolism of pulmonary surfactant.

N J Gross1, R M Schultz.   

Abstract

Pulmonary surfactant as lavaged from the alveoli exists in at least three structural subtypes, lamellar body-like, tubular myelin and vesicular forms that can be separated on the basis of their buoyant densities. Previous studies have suggested that surfactant is secreted in the lamellar body form and metabolized through the other subtypes in sequence. This metabolic sequence can be reproduced in vitro by cyclic expansion and contraction ('cycling') of the surface area of nascent surfactant at 38 degrees C. Cycling of nascent secretion, which is predominantly of lamellar body-like buoyant density, rapidly converted it to the buoyant density of tubular myelin and then to that of the vesicular subtype. We examined the role of proteinases in the conversion of nascent surfactant subtypes in vitro. Addition of metallo-, cysteine- and acid-proteinase inhibitors to the cycling mix did not inhibit the conversion of tubular myelin to vesicular subtype. However, a variety of serine proteinase inhibitors inhibited the formation of vesicular subtype. Their inhibitory effect was dose-related and most marked for alpha 1-antitrypsin where a concentration equal to that found in the alveolar fluid lining layer resulted in 50% inhibition of the generation of light subtype, suggesting physiological relevance. The enzyme(s) responsible for promoting the generation of light subtype was sedimentable and therefore presumably in particulate form. By differential centrifugation of lung secretions it was separable from alveolar macrophages and partially separable from surfactant itself. It has not been identified, nor has its substrate. We conclude that in vitro cycling provides a model for the study of alveolar surfactant metabolism and that the conversion of tubular myelin to vesicular forms of surfactant requires serine proteinase activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2344440     DOI: 10.1016/0005-2760(90)90306-i

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Pulmonary surfactant: unanswered questions.

Authors:  N J Gross
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

2.  Ozone stress initiates acute perturbations of secreted surfactant membranes.

Authors:  J U Balis; J F Paterson; J M Lundh; E M Haller; S A Shelley; M R Montgomery
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

3.  Degradation of surfactant-associated protein B (SP-B) during in vitro conversion of large to small surfactant aggregates.

Authors:  R A Veldhuizen; K Inchley; S A Hearn; J F Lewis; F Possmayer
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

4.  Effects of smoke inhalation on alveolar surfactant subtypes in mice.

Authors:  M R Oulton; D T Janigan; J M MacDonald; G T Faulkner; J E Scott
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

5.  Surfactant-associated protein A is important for maintaining surfactant large-aggregate forms during surface-area cycling.

Authors:  R A Veldhuizen; L J Yao; S A Hearn; F Possmayer; J F Lewis
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

6.  Surface-area cycling of different surfactant preparations: SP-A and SP-B are essential for large-aggregate integrity.

Authors:  R A Veldhuizen; S A Hearn; J F Lewis; F Possmayer
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

Review 7.  Surfactant alteration and replacement in acute respiratory distress syndrome.

Authors:  A Günther; C Ruppert; R Schmidt; P Markart; F Grimminger; D Walmrath; W Seeger
Journal:  Respir Res       Date:  2001-10-12

8.  Effective in vivo treatment of acute lung injury with helical, amphipathic peptoid mimics of pulmonary surfactant proteins.

Authors:  Ann M Czyzewski; Lynda M McCaig; Michelle T Dohm; Lauren A Broering; Li-Juan Yao; Nathan J Brown; Maruti K Didwania; Jennifer S Lin; Jim F Lewis; Ruud Veldhuizen; Annelise E Barron
Journal:  Sci Rep       Date:  2018-05-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.